Trials / Completed
CompletedNCT02287779
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Mirum Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHP626 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-01-19
- Primary completion
- 2015-06-19
- Completion
- 2015-06-19
- First posted
- 2014-11-11
- Last updated
- 2019-03-26
- Results posted
- 2016-12-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02287779. Inclusion in this directory is not an endorsement.